We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

65 hedge funds and large institutions have $126M invested in Adaptimmune Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 17

0.1% more ownership

Funds ownership: 11.59% → 11.69% (+0.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

6% less funds holding

Funds holding: 69 → 65 (-4)

24% less capital invested

Capital invested by funds: $166M → $126M (-$39.9M)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

61% less call options, than puts

Call options by funds: $11K | Put options by funds: $28K

Holders
65
Holders Change
-4
Holders Change %
-5.8%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
18
Reduced
17
Closed
10
Calls
$11K
Puts
$28K
Net Calls
-$17K
Net Calls Change
-$94K

Top Buyers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
+$1.78M
2
Citadel Advisors
Citadel Advisors
Florida
+$1.37M
3
Bank of America
Bank of America
North Carolina
+$1.03M
4
JP Morgan Chase
JP Morgan Chase
New York
+$469K
5
LFCM
Long Focus Capital Management
Puerto Rico
+$235K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$586K
2
KHCM
Kettle Hill Capital Management
New York
-$382K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$332K
4
Goldman Sachs
Goldman Sachs
New York
-$171K
5
GCP
GSA Capital Partners
United Kingdom
-$143K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
51
Narwhal Capital Management
Georgia
$11.3K – – –
ProShare Advisors
52
ProShare Advisors
Maryland
$11K -$2.92K -1,884 -16%
GRP
53
Global Retirement Partners
California
$8.4K +$9.29K +6,000 New
Wells Fargo
54
Wells Fargo
California
$6.76K – – –
CUAMC
55
China Universal Asset Management Company
China
$2.15K +$776 +501 +34%
Citigroup
56
Citigroup
New York
$1.8K -$476 -307 -16%
Osaic Holdings
57
Osaic Holdings
Arizona
$1.31K – – –
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
$1.22K +$282 +182 +19%
Daiwa Securities Group
59
Daiwa Securities Group
Japan
$1K – – –
NA
60
NewEdge Advisors
Louisiana
$981 – – –
WAM
61
Worth Asset Management
Texas
$654 – – –
CHA
62
Carmichael Hill & Associates
Maryland
$573 – – –
CA
63
Clearstead Advisors
Ohio
$545 – – –
ASN
64
Advisory Services Network
Georgia
$354 – – –
KHCM
65
Kettle Hill Capital Management
New York
– -$382K -261,411 Closed
Marshall Wace
66
Marshall Wace
United Kingdom
– -$130K -89,171 Closed
HSA
67
HBK Sorce Advisory
Pennsylvania
– -$65K -70,000 Closed
KI
68
Kapitalo Investimentos
Brazil
– -$53.1K -36,400 Closed
Arrowstreet Capital
69
Arrowstreet Capital
Massachusetts
– -$48K -32,586 Closed
Susquehanna International Group
70
Susquehanna International Group
Pennsylvania
– -$41.1K -28,126 Closed
CANY
71
Caxton Associates (New York)
New York
– -$37.5K -25,713 Closed
SG
72
StoneX Group
New York
– -$16.7K -11,431 Closed
Rockefeller Capital Management
73
Rockefeller Capital Management
New York
– -$2K -2,000 Closed
S
74
SignatureFD
Georgia
– -$545 -373 Closed
1 2
3

ADAP Hedge Fund Activity: Q1 2023 in Review

65 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2023, worth a combined $126M — down 24% from $166M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ADAP and 6 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 18 added.

The largest buyer was PFM Health Sciences, adding an estimated $1.78M. The largest seller was Renaissance Technologies, cutting an estimated $586K.

  • 65 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2023, down from 69 in Q4 2022.
  • Funds reported $126M of Adaptimmune Therapeutics stock for Q1 2023, down 24% quarter-over-quarter.
  • 6 funds opened new Adaptimmune Therapeutics positions in Q1 2023 and 10 closed out, a net change of -4 holders.
  • The largest Adaptimmune Therapeutics buyer in Q1 2023 was PFM Health Sciences, an estimated $1.78M added.
  • The largest Adaptimmune Therapeutics seller in Q1 2023 was Renaissance Technologies, an estimated $586K sold.

Based on aggregated 13F filings for Q1 2023.